Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in newly diagnosed CBF-AML
NCT02013648Phase 3Completed
- Sponsor
- Ulm University
- Start
- Jul 2014
- Primary completion
- Feb 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of dasatinib in acute myeloid leukemia (AML), sponsored by Ulm University. Started Jul 2014; status: completed.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02013648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013648.